<DOC>
	<DOCNO>NCT00926107</DOCNO>
	<brief_summary>The primary objective study determine efficacy Temsirolimus patient ovarian cancer CA125 relapse first-line platinum-based chemotherapy .</brief_summary>
	<brief_title>Study mTOR Inhibitor Temsirolimus ( CCI-779 ) Treat Ovarian Cancer With CA125 Only Relapse</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologic proof epithelial ovarian , fallopian peritoneal carcinoma follow histological type : serous , endometrioid , mucinous , clear cell , low differentiation . 2 . Age 18 year old 3 . Patients receive firstline platinum base chemotherapy 4 . Documented CA125 progression accord GCIC criterion . 5 . No evidence measurable evaluable disease . 6 . Provision write informed consent 7 . ECOG PS 02 8 . Life expectancy great 12 week 9 . WBC &gt; 4000/μl , platelet &gt; 100,000/μl hemoglobin level &gt; 9.5 g/dl . Adequate baseline hepatic function , define total bilirubin level &lt; 2 mg/dl , SGPT SGOT &lt; 2.5 time upper limit normal . Creatinine &lt; 1.5 mg/dl creatinine clearance &gt; 60 ml/min . 10 . All female childbearing potential must negative serum urine pregnancy test obtain within 2 day prior initiation treatment use effective contraception period therapy . 11 . At least one month last chemotherapy administration . 12 . Provision adequate paraffinembedded tumor tissue translational study ( optional ) . 1 . Other histological type ( germ cell , granulose tumor etc ) 2 . History atrial ventricular arrhythmia and/or history congestive heart failure , even medically control . History clinical electrocardiographically document myocardial infarction within last 6 month study entry 3 . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude ) 4 . Preexisting motor sensory neurotoxicity grade 2 accord WHO criteria ( intolerable paresthesia and/or mark motor loss worse ) 5 . History treatment CA125 relapse 6 . Known , severe hypersensitivity temsirolimus excipients product 7 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ 8 . Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy 9 . As judged investigator , evidence severe uncontrolled systemic disease ( eg unstable uncompensated respiratory , cardiac , hepatic renal disease ) 10 . Alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) great 2.5 time ULRR . 11 . Active infection evidence significant clinical disorder laboratory find make undesirable patient participate trial/ receive protocol treatment 12 . Concomitant use Cyp3 A inducer ( phenytoin , carbamazepine , rifampicin , barbiturates St John 's Wort ) avoid treatment strong CyP 3A inhibitor 13 . Treatment nonapproved investigational drug within 30 day Day 1 trial treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>